🇺🇸 FDA
Pipeline program

autologous FL-33 CAR T therapy

BJGBYY-IIT-LCYJ-2024-004

Phase 1 small_molecule active

Quick answer

autologous FL-33 CAR T therapy for Refractory/Relapsed Acute Myeloid Leukaemia is a Phase 1 program (small_molecule) at INTEGRATED BIOPHARMA INC with 1 ClinicalTrials.gov record(s).

Program details

Company
INTEGRATED BIOPHARMA INC
Indication
Refractory/Relapsed Acute Myeloid Leukaemia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials